CSTC1 for Diabetic Foot Ulcers Phase II Study

Charsire Biotechnology

Status and phase

Completed

Phase 2

Conditions

Diabetes Mellitus

Wounds

Diabetic Foot Ulcer

Treatments

Drug: CSTC1

Drug: CSTC1 Matched vehicle

Study type

Interventional

Funder types

Industry

Identifiers

NCT01813305

CSTC1-01

Details and patient eligibility

About

The objective of this study is to evaluate the efficacy and safety of CSTC1 in patient with diabetic foot ulcers.

Full description

This study was designed as a randomized, double-blind, vehicle-controlled, multiple-center, and parallel trial to evaluate the efficacy and safety of CSTC1 in patients with diabetic foot ulcers (DFU). In each study site, eligible patients were randomized in a 4:1 ratio to receive either one of the topical applications of CSTC1 or CSTC1 matched vehicle, topical application on target diabetic foot ulcer (DFU), 2 times daily.

The treatment duration for each subject was 12 weeks or up to confirmed complete ulcer closure, whichever comes first. That was, subjects would receive treatment for at most 12 weeks, which consists of 8 visits located at weeks 1, 2, 3, 4, 6, 8, 10, and 12. Subjects who achieved confirmed complete ulcer closure during the treatment period would be arranged for a 12 week post-treatment follow-up. Subjects failed to achieve complete ulcer closure at week-12 visit would be arranged for 4 weeks of safety follow-up. If confirmation of complete ulcer closure was reached at a week-14 visit, the subject would continue the post-treatment follow-up visit until week-24 visit. Otherwise, the subject would be arranged for safety follow-up until week-16 visit.

Enrollment

124 patients

Sex

All

Ages

20+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

With either gender aged at least 20 years old;
With a diabetic ulcer (which is defined as the target ulcer) on the foot and not healing for at least 2 weeks;
The target ulcer is classified as grade 1 or 2 ulcer according to modified Wagner system;
The target ulcer should show "infection control" at investigator's discretion;
Subject should be free of any necrosis or infection in soft and bone tissue;
Subject has signed the written informed consent form

Exclusion criteria

With active osteomyelitis;
With target ulcer size decreased by at least 50% after at least 2 weeks of standard-of-care-only period or any other recorded regular therapy before Randomization visit;
With poor nutritional status (albumin < 3g/dl), poor diabetic control (HbA1c > 12%), anemia (hemoglobin<10 g/dL), a leukocyte counts < 1,000/mm3, abnormal liver function (AST, ALT>3 x upper limit of normal range);
Requiring treatment with corticosteroids, immunosuppressive or chemotherapeutic agents;
Presence of necrosis, purulence or sinus tracts that cannot be removed by debridement;
Receiving revascularization surgery performed <8 weeks before entry in the study;
With known or suspected hypersensitivity to any ingredients of study product and vehicle;
With coronary heart disease with myocardial infarction, coronary artery bypass graft (CABG), or percutaneous transluminal coronary angioplasty (PTCA) within 3 months prior to study;
Pregnant or lactating or premenopausal with childbearing potential but not taking reliable contraceptive method(s) during the study period;
Enrollment in any investigational drug trial within 4 weeks before entering this study;
With any uncontrolled illness judged by the investigator that entering the trial may be detrimental to the subject.